Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • TriSalus Life Sciences' Change in Accured Expenses rose 17476.54% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 12531.12%. This contributed to the annual value of -$4.4 million for FY2024, which is 25447.5% down from last year.
  • Latest data reveals that TriSalus Life Sciences reported Change in Accured Expenses of $1.5 million as of Q3 2025, which was up 17476.54% from -$1.8 million recorded in Q2 2025.
  • TriSalus Life Sciences' Change in Accured Expenses' 5-year high stood at $5.4 million during Q4 2023, with a 5-year trough of -$4.6 million in Q3 2023.
  • In the last 4 years, TriSalus Life Sciences' Change in Accured Expenses had a median value of $214728.0 in 2022 and averaged $335200.0.
  • As far as peak fluctuations go, TriSalus Life Sciences' Change in Accured Expenses tumbled by 148636.36% in 2024, and later skyrocketed by 63245.9% in 2025.
  • Over the past 4 years, TriSalus Life Sciences' Change in Accured Expenses (Quarter) stood at $4.1 million in 2022, then surged by 30.69% to $5.4 million in 2023, then crashed by 94.43% to $301000.0 in 2024, then surged by 402.99% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, -$1.8 million for Q2 2025, and $1.6 million during Q1 2025.